Daré Bioscience, Inc. (DARE)

Daré Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2.82	2.81	10	-	-	-
Revenue Growth (YoY)	-71.83%	-71.92%	-	-	-	-
Cost of Revenue	21.65	21.64	30.14	0.1	0.08	0.53
Gross Profit	-18.83	-18.83	-20.14	-0.1	-0.08	-0.53
Selling, General & Admin	11.24	11.91	11.24	8.35	6.55	5.27
Research & Development	-1.69	-	-	30.62	20.77	8.55
Operating Expenses	9.55	11.91	11.24	38.97	27.32	13.81
Operating Income	-28.38	-30.74	-31.39	-39.07	-27.4	-14.34
Other Non Operating Income (Expenses)	-0.29	0.78	0.44	0	0	0.08
EBT Excluding Unusual Items	-28.67	-29.96	-30.95	-39.07	-27.4	-14.26
Other Unusual Items	-0.4	-0.4	-	0.37	-	-
Pretax Income	-28.87	-30.16	-30.95	-38.7	-27.4	-14.26
Net Income	-28.87	-30.16	-30.95	-38.7	-27.4	-14.26
Preferred Dividends & Other Adjustments	-	-	-	-	0.01	0.79
Net Income to Common	-28.87	-30.16	-30.95	-38.7	-27.41	-15.05
Shares Outstanding (Basic)	8	7	7	5	3	1
Shares Outstanding (Diluted)	8	7	7	5	3	1
Shares Change (YoY)	7.16%	3.23%	38.29%	103.23%	93.15%	45.16%
EPS (Basic)	-3.81	-4.15	-4.39	-7.59	-10.93	-11.60
EPS (Diluted)	-3.81	-4.15	-4.39	-7.59	-10.93	-11.60
Free Cash Flow	-30.19	-39.49	-18.15	-28.78	-25.25	-13.32
Free Cash Flow Per Share	-3.98	-5.43	-2.58	-5.65	-10.07	-10.26
Gross Margin	-	-	-201.42%	-	-	-
Operating Margin	-1007.38%	-1094.77%	-313.85%	-	-	-
Free Cash Flow Margin	-1071.59%	-1406.26%	-181.51%	-	-	-
EBITDA	-28.34	-30.7	-31.36	-39.04	-27.36	-14.33
D&A For EBITDA	0.04	0.04	0.02	0.03	0.04	0.01
EBIT	-28.38	-30.74	-31.39	-39.07	-27.4	-14.34
Revenue as Reported	2.82	2.81	10	-	-	-

Source: S&P Capital IQ. Standard template.